Viewing Study NCT06731803

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 7:35 PM
Ignite Modification Date: 2026-01-21 @ 4:38 AM
Study NCT ID: NCT06731803
Status: RECRUITING
Last Update Posted: 2025-04-02
First Post: 2024-12-09
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Esophagogastric Adenocarcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None gastric adenocarcinoma View
None GEJ adenocarcinoma View
None Her2 positive View